Oramed Pharmaceuticals (NASDAQ:ORMP) and Janux Therapeutics (NASDAQ:JANX) Financial Comparison

Janux Therapeutics (NASDAQ:JANX) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of current ratings for Janux Therapeutics and Oramed Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2	2	10	1	2.67
Oramed Pharmaceuticals	0	1	0	0	2.00

Janux Therapeutics presently has a consensus target price of $36.46, indicating a potential upside of 120.85%. Given Janux Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Janux Therapeutics is more favorable than Oramed Pharmaceuticals.

Earnings & Valuation

This table compares Janux Therapeutics and Oramed Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10.00 million	100.94	-$113.62 million	($1.64)	-10.07
Oramed Pharmaceuticals	$2.00 million	84.66	$64.05 million	$4.12	0.99

Oramed Pharmaceuticals has lower revenue, but higher earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Janux Therapeutics has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.

Institutional & Insider Ownership

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 20.8% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Janux Therapeutics and Oramed Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%

Summary

Janux Therapeutics beats Oramed Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Janux Therapeutics

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.